TIA Biomarkers Determined Through Proteomics (I11-1A)

Conclusions: PBP has been identified as potential serum biomarker for TIA. Larger sample size may find that ceruloplasmin is an additional candidate. Ultimately, a panel of proteins may be required. Larger studies are needed to determine the validity of these proteins in clinical use.Disclosure: Dr. George has nothing to disclose. Dr. Mlynash has nothing to disclose. Dr. Adams has nothing to disclose. Dr. Kuo has nothing to disclose. Dr. Kemp has nothing to disclose. Dr. Garcia has nothing to disclose. Dr. Albers has received personal compensation for activities with Genentech, Inc. and Lundbeck Research USA, Inc. as an advisor. Dr. Olivot has nothing to disclose.

Source: Neurology - April 8, 2015 Category: Neurology Authors: George, P., Mlynash, M., Adams, C., Kuo, C., Kemp, S., Garcia, M., Albers, G., Olivot, J.-M. Tags: The Promise of Novel Biomarker Approaches in Advancing Treatment Data Blitz Presentations Source Type: research